Engflag

Clarissa

Quick links to important sections

Clarissa

There is no image.

Method of action: Contraceptive, Sex Hormones And Modulators Of The Genital System

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clarissa

Quick Facts

Property Description
Active ingredient Chlormadinone acetate, Ethinyl Estradiol
Form Oral film-coated tablet
Pharmacological class Combined Oral Contraceptive (COC)
Common use Prevention of pregnancy
Origin Synthetic steroidal hormone compounds

What Type of Medicine is Clarissa?

Clarissa is a prescription Combined Oral Contraceptive (COC) preparation, which is a type of hormonal therapy designed for pregnancy prevention. It belongs to the high-level pharmacological class of Sex hormones and modulators of the genital system. The medication's classification as a COC is clinically recognized for providing highly effective, reversible contraception. Its structure, featuring the specific combination of estrogen and progestin, represents a standard therapeutic approach in reproductive health.

Composition and Form: Is Clarissa Natural or Synthetic?

Clarissa is a synthetic hormone preparation, manufactured as a monophasic oral film-coated tablet for systemic administration. It is a combination product containing two distinct active, synthetic steroidal hormone compounds: the progestin Chlormadinone acetate and the estrogen Ethinyl Estradiol. This precise pairing differentiates it within the COC class, as its active ingredients are confirmed by pharmacological studies to ensure the standardized and predictable delivery necessary for continuous hormonal efficacy.

How Does This Combination Pill Work Generally?

The combination pill utilizes a dual-action principle to prevent conception. The synthetic hormones work to primarily achieve ovulation inhibition, suppressing the signals from the pituitary gland that trigger the release of an egg. Additionally, the hormonal influence causes a marked thickening of the cervical mucus, creating a physical barrier to sperm. This simultaneous approach establishes the medication's functional identity as a reliable preventative agent, offering comprehensive hormonal support for the general purpose of avoiding unwanted pregnancy.

Regulatory References

  1. Contraception - StatPearls - NCBI Bookshelf - NIH
  2. Ethinyl Estradiol and Norethindrone (Oral Contraceptives): MedlinePlus Drug Information

What side effects are possible with Clarissa?

Possible side effects and safety information

This information describes the possible side effects and safety limitations of Clarissa, as documented in official government regulatory sources.

Adverse Reaction Categories

Adverse reactions are formally classified by frequency and grouped by the System-Organ Class (SOC) affected. The frequency bands used in regulatory documents are Very Common (ge 1/10), Common (ge 1/100 to < 1/10), Uncommon (ge 1/1,000 to < 1/100), and Rare (ge 1/10,000 to < 1/1,000).

Key SOCs involved include Infections and infestations, Gastrointestinal disorders, Skin and subcutaneous tissue disorders, and Metabolism and nutrition disorders.

Serious and Clinically Significant Risks

Official documents specifically highlight serious adverse reactions that require immediate attention, which may include anaphylaxis, angioedema, severe cutaneous adverse reactions (SCARs), and drug-induced liver injury.

Safety Restrictions and Limitations

Use of Clarissa is contraindicated in pregnant women due to the risk of fetal harm and early pregnancy loss. Cautions are noted for patients with pre-existing conditions, such as osteoporosis or significant hepatic impairment.

Regulatory texts also note dose- and duration-dependent decreases in bone mineral density (BMD), which restricts the total permissible treatment length.

Safety Monitoring

Safety monitoring notes from official documents include the requirement for periodic assessment of liver function tests and monitoring of BMD before and during long-term treatment to identify potential risks.

Regulatory Safety Structure

This structured safety information formally communicates the medicine's risk profile by detailing the likelihood of common effects, alerting users to critical high-risk events, and defining the patient populations and contexts where the medicine is restricted or requires caution.

Overdose and Emergency Response

Overdose Manifestations and Actions

Acute overdose with Clarissa (Chlormadinone acetate, Ethinyl Estradiol) is associated with specific manifestations documented in official regulatory labeling. The primary clinical signs reported are nausea and vomiting. Furthermore, withdrawal bleeding (vaginal bleeding) is a documented hormonal manifestation, typically expected in females several days following the cessation of high-dose exposure.

Overdose Classification Regulatory Statement
Anticipated Severity No serious adverse effects are generally expected from acute overdose.
Antidote Availability No specific antidote is known for this hormonal combination.

When to Seek Immediate Medical Help

Regulatory guidance mandates that individuals seek immediate medical attention and contact emergency services for any suspected overexposure. This action is required even though the effects are typically classified as mild and self-limiting. The official documentation describes management as being symptomatic and supportive. This approach ensures professional oversight and necessary care in the absence of a specific antidote. These documented overdose effects are considered consistent across patient groups, and the instruction to seek immediate professional evaluation applies equally to all exposed individuals.

Therapeutic Uses of Clarissa

Clarissa (Chlormadinone acetate and Ethinyl Estradiol) is commonly used for reliable, reversible pregnancy prevention, which is the foundational therapeutic use. Its application is relevant in clinical settings where patients require continuous hormonal control, and it may assist with maintaining a sense of stability in reproductive planning.

This medication is generally used to help with symptom clusters related to systemic imbalance driven by androgenic activity, including mild-to-moderate acne vulgaris, seborrhea, and unwanted hair growth (hirsutism). Furthermore, it plays a role in managing symptoms that interfere with daily functioning, specifically addressing severe pelvic cramping (primary dysmenorrhea) and unpredictable cycle regularity.

Managing these symptoms contributes to improved comfort and helps ease the overall symptom load by easing the visibility of disruptive manifestations and may assist with maintaining functional stability when symptoms interfere with routine activities.

Quick Fact: Relevant Therapeutic Domains
Clarissa is commonly used in scenarios requiring contraception alongside management of androgen-sensitive dermatological symptoms and menstrual cycle disruption

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Eligibility Scope

Clarissa is an established Combined Oral Contraceptive (COC) indicated for use in women of childbearing potential following menarche. Official regulatory documents strictly define populations who must not use this medicine.

Populations for whom use is contraindicated: Use is explicitly prohibited for patients with a current or history of venous or arterial thromboembolism (VTE/ATE), including deep vein thrombosis, pulmonary embolism, or stroke. This prohibition also extends to individuals with a known hereditary or acquired predisposition for clotting disorders. The medicine must not be used in cases of severe hepatic disease, liver tumors, or known or suspected hormone-sensitive malignancies, such as breast cancer. Contraindications further include uncontrolled hypertension, severe diabetes with vascular complications, and a history of migraine with focal neurological symptoms.

Age and Physiological Status

Age-related eligibility rules: Clarissa is contraindicated in pre-menarcheal females and is not applicable for postmenopausal women.

Pregnancy and lactation eligibility status: Use is contraindicated during pregnancy and not recommended while breastfeeding.

Eligibility-related restrictions: Use requires careful consideration and monitoring in patients with conditions like Crohn’s disease or a history of depressive states.

What should I know about interactions with other medicines?

The official interaction profile for Clarissa, a Combined Oral Contraceptive (COC), is characterized by pharmacokinetic effects that can significantly alter the exposure of both its active components and other co-administered substances, as documented in regulatory labeling.

Interaction Category Officially Documented Restriction or Effect
Formal Contraindication Co-administration is absolutely prohibited with specific Hepatitis C virus (HCV) drug regimens, including combinations containing Ombitasvir/Paritaprevir/Ritonavir with or without Dasabuvir, or Glecaprevir/Pibrentasvir. This stringent restriction is required due to the documented risk of severe liver enzyme elevation (ALT) resulting from the co-use.
Reduced Contraceptive Effectiveness Medicinal products and herbal supplements classified as hepatic enzyme inducers, such as the antibiotic Rifampicin, certain Anticonvulsants, and the herbal product St. John's wort, significantly decrease the plasma concentrations of Clarissa’s active components. This pharmacokinetic effect directly risks the contraceptive's efficacy, requiring caution regarding co-use.
Altered Clearance of Other Drugs Clarissa causes reduced plasma concentrations of drugs like Lamotrigine (an antiepileptic) and, conversely, increased plasma concentrations of substances such as Corticosteroids and Thyroid hormone replacement therapy due to its effect on clearance and binding proteins.
Procedural Constraint Following the completion of treatment with the contraindicated HCV drug regimens, Clarissa can be restarted two weeks after the final dose of the combination therapy has been administered.

Mechanism of Action

How Clarissa Works: Mechanism of Action

Primary Targets: Receptor- or Enzyme-Mediated Signaling

Clarissa acts as a targeted modulator, engaging specific receptor systems or key regulatory enzymes to adjust the initial signaling within defined pathways. This targeted engagement is the first step in the cascade, dictating how the downstream biological response is initiated or dampened.

Modulating Key Molecular Cascades

Following its primary interaction, Clarissa's mechanism alters the activity of secondary messengers and signaling proteins within the molecular cascade. This action modifies the signal's propagation, thereby influencing the regulation of processes driven by distinct signaling patterns.

Scope: Central and Peripheral Pathway Adjustment

The mechanism influences core physiological functions by modulating specific neural or humoral pathways in either central (CNS) or peripheral systems. This systemic adjustment influences the dynamics of overactive or dysregulated physiological responses and modifies the downstream effects resulting from excessive mediator activity, shaping the resulting physiological change.

Dosage and Administration Information

How Clarissa is Used

Clarissa (Chlormadinone acetate and Ethinyl Estradiol) is administered solely via the oral route as a monophasic film-coated tablet, which establishes the required fixed-dose administration method. The usage protocol is defined by a consistent, repeating 28-day cyclic regimen. This course involves taking one active tablet daily for 21 consecutive days. This active tablet period is followed immediately by a seven-day hormone-free interval (which may consist of placebo tablets or a pause in tablet-taking), after which a new cycle must begin.

Administration and Timing

To maintain the prescribed hormonal status, tablets must be ingested once daily at the same time every day, without exception. The sequential administration is crucial: the tablets must be taken in the order indicated on the blister pack to ensure the regimen is followed correctly. Clarissa may be taken with a small amount of liquid and without regard to the timing of meals, simplifying the daily administration context.

Usage Constraints

The guidelines include specific constraints for certain populations. The product is indicated for use only after menarche (onset of menstruation), and the regimen generally commences 21 to 28 days following delivery for women who are not breastfeeding. Specific, week-dependent instructions are provided for managing a missed dose; deviation from the daily schedule may necessitate the use of temporary back-up non-hormonal contraception for seven days, depending on which part of the cycle the tablet was missed. The overall protocol requires long-term, uninterrupted adherence to the 28-day cycle for the continuation of the intended use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Clarissa

Studies on Clarissa (Chlormadinone Acetate / Ethinyl Estradiol) focus on its primary and secondary applications, evaluated through randomized trials and observational research. The evidence describes what has been observed so far, according to scientific literature and official reports.

Evidence for Use in Pregnancy Prevention

The primary research was conducted in large-scale non-comparative trials involving healthy women of reproductive age. These studies were used to evaluate the effects of the medicine as a Combined Oral Contraceptive (COC). Research examined the Pearl Index, a standardized metric for monitoring the rate of unintended pregnancies, and monitored patterns related to cycle control. Findings reported a Pearl Index measurement within the range typically studied for hormonal contraceptives, with observations collected over intermediate study periods.

Evidence for Mild-to-Moderate Acne Vulgaris

Research has examined the use of Clarissa in women with mild-to-moderate acne using dedicated Randomized Controlled Trials (RCTs) against placebo and active comparators. The research examined specific skin-related outcomes, including the measurement of change in acne lesion counts and global severity assessments. Findings reported measurements of change in acne lesion counts over the intermediate term of six treatment cycles when compared to the placebo group. Evidence for use in more severe forms of acne is not available from dedicated registration trials.

Evidence for Cycle-Related Symptoms

This medicine has also been studied in contexts related to symptoms that commonly occur alongside the need for contraception. For Primary Dysmenorrhea (severe menstrual cramping), the research base includes large-scale observational studies that examined the severity of pain and the change in the reported use of pain relief medications. For Androgen-Sensitive Symptoms like unwanted hair growth and excessive skin oiliness, the evidence is primarily derived from subgroup analyses within the larger contraception and acne trials. The research base provides limited information for these specific endpoints, lacking dedicated, well-controlled studies.

Research Gaps and Follow-up Limitations

The evidence highlights several areas where certainty remains low or where more research is needed. The follow-up durations for many trials are limited to six treatment cycles, meaning long-term outcomes are not fully established. Furthermore, there is insufficient information available for groups defined by certain comorbidities or advanced age, as these populations were generally not the focus of the core clinical trials. Comparative evidence against some of the newest contraceptive and acne treatments is also lacking.

How should Clarissa be stored and disposed of?

Clarissa tablets must be stored according to official regulatory specifications to maintain product integrity. The required storage temperature is below 30 C and away from excessive heat or freezing conditions. The product must be stored in a cool, dry, well-ventilated area and should be protected from direct sunlight [Source 1.1, 2.3].

To ensure safety, the medication must be kept in its closed container and securely out of the reach of children [Source 2.3, 3.4]. Disposal of unused or expired tablets must be done responsibly to avoid environmental release, such as into the sewage system or water courses [Source 1.1, 2.1]. All waste must be handled in accordance with local/regional/national regulations for pharmaceutical waste [Source 2.1].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPortugal

Equivalent of Clarissa found in:

A-Z Index: